Arcus Biosciences (RCUS) Misses Q4 EPS by 6c

Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($1.08), $0.06 worse than the analyst estimate of ($1.02). Revenue for the quarter came in at $31 million versus the consensus estimate of $29.03 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Rothschild Redburn Upgrades Apple (AAPL) to Buy
• Empire Petroleum posts $11.1M revenue in Q2 2026, narrows net loss